Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13675MR)

This product GTTS-WQ13675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13675MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ113MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ8067MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14595MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ5894MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ4245MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ2267MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ13228MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ6872MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW